Clinical Trial Update: Effects of Intrathecal Dexmedetomidine as an Adjuvant to Low Dose Hyperbaric 0.5% Bupivacaine [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating intrathecal dexmedetomidine as an adjuvant to low-dose hyperbaric bupivacaine for postoperative pain, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postoperative Pain

Drugs mentioned

• bupivacaine 0.5% (intrathecal) (bupivacaine)
• dexmedetomidine (intrathecal) (dexmedetomidine)

Snippet

Sponsor: Sindh Institute of Urology and Transplantation | Conditions: Post Operative Pain | Phase 4 | Status: COMPLETED